LYB001

LYB001
Vaccine description
Target	SARS-CoV-2
Vaccine type	Virus-like particles
Clinical data
Routes of; administration	Intramuscular

LYB001 is a COVID-19 vaccine candidate developed by Yantai Patronus Biotech Co., Ltd.[1][2][3][4]

References

"Safety, Reactogenicity, and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine LYB001 in healthy adults: a randomized, double blinded, placebo-controlled phase I trial". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 15 October 2021.
"A Phase I Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine LYB001". ClinicalTrials.gov. 18 November 2021. NCT05125926. Retrieved 18 November 2021.
"Immunogenicity and safety of a SARS-CoV-2 Vaccine LYB001 against COVID-19 in healthy adults: a randomized, double blinded, placebo-controlled phase II trial and a single-armed, open-label expanded safety phase III trial". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 15 October 2021.
"Phase II and III Trial of a SARS-CoV-2 Vaccine LYB001". ClinicalTrials.gov. 30 November 2021. NCT05137444. Retrieved 30 November 2021.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Safety, Reactogenicity, and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine LYB001 in healthy adults: a randomized, double blinded, placebo-controlled phase I trial". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 15 October 2021.

[2] "A Phase I Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine LYB001". ClinicalTrials.gov. 18 November 2021. NCT05125926. Retrieved 18 November 2021.

[3] "Immunogenicity and safety of a SARS-CoV-2 Vaccine LYB001 against COVID-19 in healthy adults: a randomized, double blinded, placebo-controlled phase II trial and a single-armed, open-label expanded safety phase III trial". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 15 October 2021.

[4] "Phase II and III Trial of a SARS-CoV-2 Vaccine LYB001". ClinicalTrials.gov. 30 November 2021. NCT05137444. Retrieved 30 November 2021.

COVID-19 pandemic
Part of a series on the
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Investigations into origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Netherlands Ghana India New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Animals Black people Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBT community Long-term care Media coverage Mental health symptoms Migration Military Notable deaths Other health issues Politics diplomacy Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Society Ireland Malaysia New Zealand Russia UK US
COVID-19 portal